The National Health Research Institutes and institute of biotechnology and pharmaceutical research’s drugs against hepatitis C virus research team with “novel small molecule inhibitors of hepatitis C virus DBPR110 of drug discovery and development,” has been selected to 2016 Taipei Biotech Award for “Technology Transfer Award.” The national health research institutes had this honor again after winning the gold medal in Technology Transfer Award with “DBPR108 anti-diabetic drug candidate” last year. The DBPR110 research outcome also received awards from the ministry of science and technology and intellectual property office belong to the ministry of economic affairs respectively before; it demonstrates the national health research institutes’ effort to facilitate the technology transfer and elevate the technology of biotechnology and pharmaceutical industry.

The national health research institutes had successfully done the DBPR110 (now known as MB110) technology transfer to Microbio in April 2013 after accomplishing pre-clinical stage of development, and the Microbio Co., Ltd. will take over the follow-up research and development work. Microbio Co., Ltd. has completed the GMP compound enlarged synthesis and development process and pre-clinical safety pharmacology tests in year 2013 & 2015, also successfully passed the formal new drug review (IND) test of the US Food and Drug Administration (FDA), the planning of clinical trials are also actively underway.